Weekly Digest – March 2025 Weekly Digest – March 2025 27 Mar 2025: TIVDAK (Tisotumab vedotin) approved by Japan Ministry of Health, Labour and Welfare for the treatment of advanced or recurrent Cervical cancer that has progressed on or after […]
Weekly Digest – March 2025 Weekly Digest – March 2025 24 Mar 2025: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer Innovent Biologics has successfully dosed the first participant in […]
Weekly Digest – March 2025 Weekly Digest – March 2025 21 Mar 2025: MacroGenics pulls plug on Vobra duo ADC after seeing phase 2 prostate cancer data MacroGenics decided to halt the development of Vobramitamab duocarmazine (Vobra duo) after reviewing […]
Weekly Digest – March 2025 Weekly Digest – March 2025 24 Mar 2025: AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets AbbVie has sued Genmab, alleging that the company misappropriated trade secrets related to antibody-drug conjugate (ADC) technology, which […]
Weekly Digest – March 2025 Weekly Digest – March 2025 21 Mar 2025: Eisai’s abandoned Enhertu challenger set to live on at BlissBio Eisai decided not to exercise its option to acquire BB-1701, a HER2-directed antibody-drug conjugate (ADC) from Bliss […]
Weekly Digest – March 2025 Weekly Digest – March 2025 26 Mar 2025: GV20 Therapeutics announces collaboration agreement with Mitsubishi Tanabe Pharma Corporation to develop novel antibody-drug conjugates GV20 Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic […]
Weekly Digest – March 2025 Weekly Digest – March 2025 18 Mar 2025: JSKN003 was granted Breakthrough Therapy Designation in China JSKN003, a HER2-targeting ADC, has been granted BTD by China’s National Medical Products Administration (NMPA) for the treatment of […]
Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: DATROWAY launched in Japan as the first TROP2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer DATROWAY (datopotamab deruxtecan) […]
Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on AstraZeneca has released early data from a Phase 2 trial […]
Weekly Digest – March 2025 Weekly Digest – March 2025 20 Mar 2025: Elevation Oncology to discontinue development of EO-3021, advancing EO-1022 while evaluating strategic options Elevation Oncology will discontinue development of EO-3021, a Claudin 18.2 ADC, after Phase 1 […]
